Christian Itin

CEO and Chairman of the Board of Directors

Autolus

Dr Christian Itin is the Chief Executive Officer and Chairman of the Board of Directors at Autolus, a biopharmaceutical company developing next generation programmed T-cell therapies for the treatment of cancer. Previously he was Chief Executive Officer and Chairman of the Board of Directors of Cytos Biotechnology Ltd, a public biotechnology company that merged with Kuros Biosurgery Holding Ltd. He now serves as a Non-Executive Director of the merged entity, renamed Kuros Biosciences Ltd. He also serves as a Non-Executive Director of the Cambridge-based human antibody company, Kymab Ltd. Prior to joining Cytos, Christian was President and Chief Executive Officer of Micromet Inc., a formerly Nasdaq-listed biopharmaceutical company which was acquired in March 2012 by Amgen Inc. for $1.2bn. Micromet pioneered T-cell engaging antibodies and with blinatumomab developed the first approved product in this field.